PDCD1 and non-small cell lung carcinoma: Anti‐PD‐1 therapy has left an indelible mark in the field of non‐small‐cell lung cancer (NSCLC) treatment; however, its efficacy is limited in clinical practice owing to differences in the degree of effector T‐cell exhaustion.